Trial Profile
An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Perampanel (Primary)
- Indications Partial epilepsies
- Focus Pharmacokinetics; Registrational
- Acronyms Study 232
- Sponsors Eisai Inc
- 06 Dec 2022 Results of post hoc pooled analysis of Phase III Studies 332 (NCT01393743) and 311 (NCT02849626), and Phase II Study 232 (NCT01527006) to assess the effect of adjunctive perampanel on myoclonic or absence seizure-free days presented at the 76th Annual Meeting of the American Epilepsy Society
- 01 Sep 2021 Results (n=393) of post-hoc analysis of patients years in studies (332/311/232) presented at the 34th International Epilepsy Congress
- 22 Apr 2021 Results of Post Hoc Pooled Analysis of Adult, Adolescent, and Pediatric Patients in Studies 332, 311, and 232 presented at the 73rd Annual Meeting of the American Academy of Neurology